Tempus Partners with Blood Cancer United to Develop Pediatric Leukemia Registry
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy TEM?
Source: Newsfilter
- Strategic Collaboration: Tempus AI and Blood Cancer United have announced a partnership to develop a patient-centered real-world registry for pediatric acute myeloid leukemia, aimed at empowering patients with health data and driving scientific breakthroughs.
- Technology Platform Utilization: The initiative will leverage Tempus' olivia app to centralize patient health data and provide personalized educational materials, ensuring patients receive timely and relevant information throughout their treatment journey, thereby enhancing patient experience and engagement.
- Data Collection and Analysis: olivia will collect longitudinal electronic patient-reported outcomes and questionnaire data, combined with Tempus' Lens analytics platform, to create one of the largest pediatric acute myeloid leukemia registries to date, facilitating the development of new therapies.
- Future Outlook: This collaboration not only provides better support and resources for pediatric leukemia patients but also accelerates clinical trial processes by integrating patient-reported outcomes with de-identified medical and genomic data, ensuring more children can access innovative therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 50.880
Low
76.00
Averages
84.38
High
105.00
Current: 50.880
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tempus Partners with Blood Cancer United to Develop Pediatric Leukemia Registry
- Strategic Collaboration: Tempus AI and Blood Cancer United have announced a partnership to develop a patient-centered real-world registry for pediatric acute myeloid leukemia, aimed at empowering patients with health data and driving scientific breakthroughs.
- Technology Platform Utilization: The initiative will leverage Tempus' olivia app to centralize patient health data and provide personalized educational materials, ensuring patients receive timely and relevant information throughout their treatment journey, thereby enhancing patient experience and engagement.
- Data Collection and Analysis: olivia will collect longitudinal electronic patient-reported outcomes and questionnaire data, combined with Tempus' Lens analytics platform, to create one of the largest pediatric acute myeloid leukemia registries to date, facilitating the development of new therapies.
- Future Outlook: This collaboration not only provides better support and resources for pediatric leukemia patients but also accelerates clinical trial processes by integrating patient-reported outcomes with de-identified medical and genomic data, ensuring more children can access innovative therapies.
See More
Tempus AI Shares Rise as Analyst Reiterates Buy Rating
- Analyst Rating Reiteration: Needham analyst Ryan MacDonald reiterated a Buy rating on Tempus AI with a $75 price target, reflecting confidence in the company's growth potential and likely attracting more investor interest.
- Research Findings Published: Tempus announced a new study in JCO Precision Oncology that highlights the value of advanced genomic profiling tools in identifying clinically actionable findings in community oncology, potentially solidifying the company's leadership in precision medicine.
- Actionable Findings Ratio: The study revealed that approximately 12% of patients in the pilot and expanded cohorts had potentially actionable findings linked to approved therapies identified solely through advanced testing features, indicating the effectiveness of the company's technology and market demand.
- Stock Price Volatility Trend: Despite Tempus AI's stock experiencing fluctuations from $37.23 to $103.25 over the past year, it currently trades at $52.85, remaining below its 20-day, 50-day, and 200-day moving averages, signaling ongoing downside pressure.
See More
Tempus AI Study Advances Precision Medicine with Genomic Profiling
- Significant Findings: A study by Tempus AI in collaboration with The Oncology Institute reveals that 12% (approximately 1 in 8) of patients identified actionable findings through advanced genomic profiling techniques, such as tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing, underscoring the importance of comprehensive genomic profiling in community oncology.
- Need for Precision Medicine: The research highlights that current treatment guidelines lack specificity regarding the composition of genomic profiling panels, emphasizing the clinical necessity of utilizing the most comprehensive tools available to ensure patients receive optimal treatment options, thereby enhancing Tempus's strategic position in precision medicine.
- Expanded Clinical Applications: By providing a more comprehensive view of clinically relevant findings, Tempus's advanced testing capabilities not only broaden access to targeted treatments and clinical trial opportunities but also equip clinicians with richer information support, facilitating the implementation of precision medicine.
- Innovation-Driven Technology: Tempus leverages one of the world's largest multimodal data libraries and applies artificial intelligence to advance precision medicine, aiming to deliver personalized treatment solutions for each patient through continuous learning and data accumulation, further solidifying its leadership in the healthcare technology sector.
See More
Tempus AI Partners with Merck for AI-Driven Precision Medicine
- Strategic Collaboration: Tempus AI has signed a strategic collaboration agreement with Merck aimed at accelerating AI-driven precision medicine, leveraging Tempus' multimodal data library and advanced Lens platform to enhance the discovery and development of precision medicine biomarkers.
- Market Impact: Despite the strategic significance of the partnership with Merck, Tempus' stock is under pressure due to broader market declines, with the S&P 500 and Nasdaq falling by 1.78% and 2.18%, respectively, indicating the influence of market sentiment on individual stocks.
- Financial Performance: In its latest earnings report, Tempus reported a quarterly loss of four cents per share, in line with expectations, while quarterly revenue reached $367.21 million, exceeding the Street estimate of $362.29 million and representing an 83% increase from $200.68 million in the prior year.
- Technical Analysis: Tempus' stock is currently trading 9.8% below its 100-day simple moving average, indicating potential weakness in the long-term trend, with an RSI of 44.45 suggesting neutral market conditions, and a MACD of 0.15 below its signal line of 0.22 indicating bearish pressure.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, which positions VentriPoint favorably for market share expansion.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' dual demand for economic value and clinical accuracy, making VentriPoint's VMS+™ system well-suited to meet this market need.
- Strategic Partnership: The commercial agreement between VentriPoint and LG Consulting Solutions will support the deployment of the VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of VMS+™, thereby accelerating technology adoption.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform to support hospital engagement, clinician training, and economic value assessments, which not only enhances cardiac care pathways but also presents potential revenue-sharing opportunities for VentriPoint.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, significantly enhancing VentriPoint's market opportunities.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' demand for economic value alongside clinical accuracy, positioning VentriPoint's VMS+™ system to meet this critical need.
- Strategic Partnership: VentriPoint has signed a commercial agreement with LG Consulting Solutions to support the deployment of its VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of the technology.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform aimed at supporting hospital engagement, clinician training, and economic value assessments, thereby accelerating the adoption of new medical technologies.
See More
Tempus Partners with Blood Cancer United to Develop Pediatric Leukemia Registry
- Strategic Collaboration: Tempus AI and Blood Cancer United have announced a partnership to develop a patient-centered real-world registry for pediatric acute myeloid leukemia, aimed at empowering patients with health data and driving scientific breakthroughs.
- Technology Platform Utilization: The initiative will leverage Tempus' olivia app to centralize patient health data and provide personalized educational materials, ensuring patients receive timely and relevant information throughout their treatment journey, thereby enhancing patient experience and engagement.
- Data Collection and Analysis: olivia will collect longitudinal electronic patient-reported outcomes and questionnaire data, combined with Tempus' Lens analytics platform, to create one of the largest pediatric acute myeloid leukemia registries to date, facilitating the development of new therapies.
- Future Outlook: This collaboration not only provides better support and resources for pediatric leukemia patients but also accelerates clinical trial processes by integrating patient-reported outcomes with de-identified medical and genomic data, ensuring more children can access innovative therapies.
See More
Tempus AI Shares Rise as Analyst Reiterates Buy Rating
- Analyst Rating Reiteration: Needham analyst Ryan MacDonald reiterated a Buy rating on Tempus AI with a $75 price target, reflecting confidence in the company's growth potential and likely attracting more investor interest.
- Research Findings Published: Tempus announced a new study in JCO Precision Oncology that highlights the value of advanced genomic profiling tools in identifying clinically actionable findings in community oncology, potentially solidifying the company's leadership in precision medicine.
- Actionable Findings Ratio: The study revealed that approximately 12% of patients in the pilot and expanded cohorts had potentially actionable findings linked to approved therapies identified solely through advanced testing features, indicating the effectiveness of the company's technology and market demand.
- Stock Price Volatility Trend: Despite Tempus AI's stock experiencing fluctuations from $37.23 to $103.25 over the past year, it currently trades at $52.85, remaining below its 20-day, 50-day, and 200-day moving averages, signaling ongoing downside pressure.
See More
Tempus AI Study Advances Precision Medicine with Genomic Profiling
- Significant Findings: A study by Tempus AI in collaboration with The Oncology Institute reveals that 12% (approximately 1 in 8) of patients identified actionable findings through advanced genomic profiling techniques, such as tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing, underscoring the importance of comprehensive genomic profiling in community oncology.
- Need for Precision Medicine: The research highlights that current treatment guidelines lack specificity regarding the composition of genomic profiling panels, emphasizing the clinical necessity of utilizing the most comprehensive tools available to ensure patients receive optimal treatment options, thereby enhancing Tempus's strategic position in precision medicine.
- Expanded Clinical Applications: By providing a more comprehensive view of clinically relevant findings, Tempus's advanced testing capabilities not only broaden access to targeted treatments and clinical trial opportunities but also equip clinicians with richer information support, facilitating the implementation of precision medicine.
- Innovation-Driven Technology: Tempus leverages one of the world's largest multimodal data libraries and applies artificial intelligence to advance precision medicine, aiming to deliver personalized treatment solutions for each patient through continuous learning and data accumulation, further solidifying its leadership in the healthcare technology sector.
See More
Tempus AI Partners with Merck for AI-Driven Precision Medicine
- Strategic Collaboration: Tempus AI has signed a strategic collaboration agreement with Merck aimed at accelerating AI-driven precision medicine, leveraging Tempus' multimodal data library and advanced Lens platform to enhance the discovery and development of precision medicine biomarkers.
- Market Impact: Despite the strategic significance of the partnership with Merck, Tempus' stock is under pressure due to broader market declines, with the S&P 500 and Nasdaq falling by 1.78% and 2.18%, respectively, indicating the influence of market sentiment on individual stocks.
- Financial Performance: In its latest earnings report, Tempus reported a quarterly loss of four cents per share, in line with expectations, while quarterly revenue reached $367.21 million, exceeding the Street estimate of $362.29 million and representing an 83% increase from $200.68 million in the prior year.
- Technical Analysis: Tempus' stock is currently trading 9.8% below its 100-day simple moving average, indicating potential weakness in the long-term trend, with an RSI of 44.45 suggesting neutral market conditions, and a MACD of 0.15 below its signal line of 0.22 indicating bearish pressure.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, which positions VentriPoint favorably for market share expansion.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' dual demand for economic value and clinical accuracy, making VentriPoint's VMS+™ system well-suited to meet this market need.
- Strategic Partnership: The commercial agreement between VentriPoint and LG Consulting Solutions will support the deployment of the VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of VMS+™, thereby accelerating technology adoption.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform to support hospital engagement, clinician training, and economic value assessments, which not only enhances cardiac care pathways but also presents potential revenue-sharing opportunities for VentriPoint.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, significantly enhancing VentriPoint's market opportunities.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' demand for economic value alongside clinical accuracy, positioning VentriPoint's VMS+™ system to meet this critical need.
- Strategic Partnership: VentriPoint has signed a commercial agreement with LG Consulting Solutions to support the deployment of its VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of the technology.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform aimed at supporting hospital engagement, clinician training, and economic value assessments, thereby accelerating the adoption of new medical technologies.
See More
